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Objective. Reliable and objective outcome mea-
sures to facilitate clinical trials of novel treatments for sys-
temic sclerosis (SSc)–related Raynaud’s phenomenon
(RP) are badly needed. Laser speckle contrast imaging
(LSCI) and thermography are noninvasive measures of
perfusion that have shown excellent potential. This multi-
center study was undertaken to determine the reliability
and validity of a hand cold challenge protocol using LSCI,
standard thermography, and low-cost cell phone/mobile
phone thermography (henceforth referred to as mobile
thermography) in patients with SSc-related RP.
Methods. Patients with RP secondary to SSc were
recruited from 6 UK tertiary care centers. The patients
underwent cold challenge on 2 consecutive days. Changes
in cutaneous blood flow/skin temperature at each visit were
imaged simultaneously using LSCI, standard thermogra-
phy, and mobile thermography. Measurements included
area under the curve (AUC) for reperfusion/rewarming
and maximum blood flow rate/skin temperature after
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rewarming (MAX). Test–retest reliability was assessed
using intraclass correlation coefficients (ICCs). Estimated
latent correlations (estimated from multilevel models, tak-
ing values between 1 and 1; denoted as rho values) were
used to assess the convergent validity of LSCI and ther-
mography.
Results. In total, 159 patients (77% with limited
cutaneous SSc) were recruited (84% female, median age
63.3 years). LSCI and standard thermography both had
substantial reliability, with ICCs for the reperfusion/re-
warming AUC of 0.67 (95% confidence interval [95% CI]
0.54, 0.76) and 0.68 (95% CI 0.58, 0.80), respectively, and
ICCs for the MAX of 0.64 (95% CI 0.52, 0.75) and 0.72
(95% CI 0.64, 0.81), respectively. Very high latent correla-
tions were present for the AUCs of LSCI and thermography
(q = 0.94; 95% CI 0.87, 1.00) and for the AUCs of standard
and mobile thermography (q = 0.98; 95% CI 0.94, 1.00).
Conclusion. This is the first multicenter study to
examine the reliability and validity of cold challenge
using LSCI and thermography in patients with SSc-
related RP. LSCI and thermography both demonstrated
good potential as outcome measures. LSCI, standard
thermography, and mobile thermography had very high
convergent validity.
Systemic sclerosis (SSc)–related digital vasculopathy
is painful and disabling, and has significant impact on quality
of life. Raynaud’s phenomenon (RP) occurs in most patients
with SSc (96%) and is consistently the highest ranked symp-
tom of SSc in terms of frequency and impact on daily func-
tion (1,2). In patients with SSc, RP often progresses to
severe digital vasculopathy, with up to 50% of patients devel-
oping painful digital ulceration (3–11).
Treatments are far from ideal, and Cochrane reviews
(http://www.cochranelibrary.com) as well as other reviews
have highlighted the lack of evidence base for the treatment
of both primary and SSc-related RP (12–15). One of the
reasons for this shortcoming is the lack of reliable outcome
measures, which are necessary to deliver successful clinical
trials. Technological advances in laboratory measurements
of blood flow (laser speckle contrast imaging [LSCI] and
thermography [skin temperature, a pseudo measure of per-
fusion]) hold promise as objective outcome measures
(16,17). The Outcome Measures in Rheumatology 6
(OMERACT 6) report, describing the current status of out-
come measure development for clinical trials in SSc, con-
cluded that whether imaging techniques made the transition
from research pathophysiologic measurement techniques to
outcome measures for RP was dependent on whether “data
are published or available to show their validity” (18). The
requirement for reliable outcome measures to facilitate
highly powered clinical trials in SSc-related RP is now espe-
cially pertinent due to ongoing novel drug developments
(19–23). Whereas patient-reported outcome measures such
as theRaynaud’s condition score (RCS; ameasure of RP dis-
ease activity with a possible score range of 0–10, with higher
scores indicating more active disease) (24) are well suited for
later (i.e., phase III) studies, objective, noninvasive imaging
techniques would provide confirmatory testing to inform
stop–go decision-making in earlier (i.e., phase II) studies.
Our main aim in the present study was to deter-
mine whether LSCI and thermography, performed subse-
quent to application of a cold challenge to the hands, are
sufficiently reliable and valid to allow their use as out-
come measures in multicenter clinical trials. Our primary
objectives were to evaluate test–retest reliability and con-
struct validity (25), which we defined as the ability of
LSCI and thermography to measure important features of
SSc-related digital vasculopathy. Our secondary objectives
were to assess the interobserver reliability, as well as feasi-
bility, of the techniques. Just prior to commencement of
our study, cell phone/mobile phone thermography (hence-
forth referred to as mobile thermography) came on the
market as an imaging method, potentially offering a more
cost-effective and portable alternative to LSCI and “stan-
dard” thermography. Thus, an additional secondary
objective was to assess the utility of mobile thermography
in comparison to standard thermography.
PATIENTS AND METHODS
Patients. Six UK tertiary care centers that provide clini-
cal care to patients with SSc took part in the study. Individuals
responsible for imaging and analysis attended a central training
session prior to the start of recruitment. At least one person
from each center attended the training.
The study aimed to recruit 180 patients with SSc (for the
inclusion and exclusion criteria used, including current digital
ulceration, see Supplementary Table 1, available on the Arthritis
& Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.40457/abstract). The study was approved by the
Cambridgeshire and Hertfordshire National Research Ethics
Service Committee (approval number 15/EE/0083), and all
patients gave written consent to participate.
All patients were recruited between October 1, 2015 and
February 28, 2016, to minimize interindividual variation related
to season. Each visit took ~1 hour.
Imaging equipment. An LSCI thermal camera (FLPI-2;
Moor Instruments) (16,17) was leased to each center (Fig-
ures 1A and 2B). Five of the 6 centers used their own thermal
cameras (referred to as “standard thermography”) (Figures 1A,
B, and D) (26), and the sixth center leased a camera. A mobile
phone/device–connectable thermography camera (FLIR One)
(Figures 1A and C) and an Apple iPhone 5 were purchased for
each center, along with all other cold challenge equipment, to
minimize variation between centers. Furthermore, to minimize
differences between centers, equipment at each site was set up
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according to strict guidelines for positioning to ensure images
were obtained in as similar a manner as possible (in terms of
angles and distances), and a calibration protocol was applied to
the equipment at the start and end of the study (carried out by a
single person from the central site [EJM]). LSCI settings were
adjusted for distance, frequency, duration, focus, intensity over-
lay, processing mode (high resolution), and color image acquisi-
tion. Thermal camera settings were adjusted for room
temperature, distance to hands, and skin emissivity. Mobile ther-
mography settings were limited but the “matte” emissivity setting
was chosen.
Cold challenge. Patients were requested to wear light
clothing and refrain from vigorous exercise, caffeine, and alcohol
for 4 hours prior to the assessment. Upon arrival, patients were
seated comfortably for 20 minutes and acclimatized, and clinical
research forms were completed. Immediately prior to the cold
challenge, a baseline image of both hands (dorsal aspect) was
obtained with LSCI and both thermal cameras. As required for
LSCI imaging, all images were acquired in low-lit rooms.
The patient’s hands were placed on a black, thermally
insulated surface (1 meter away from the thermal cameras and 70
cm [5 cm] from the LSCI). Small sticky dots were used to mark
the location of each finger at baseline. Both hands were placed in
nitrile gloves and immersed to the metacarpophalangeal joints for
1 minute into cooled water (temperature of 15C [1C], mea-
sured by calibrated thermometer) in 2 standard containers, one
on either side of the patient. After the cold challenge, the gloves
were removed and the hands were returned to their original posi-
tion on the insulating surface, secured by double-sided sticky tape
to avoid movement between images.
Reperfusion/rewarming after application of the cold chal-
lenge was imaged simultaneously by LSCI at 15 frames per min-
ute, and thermography at 4 frames per minute, for 15 minutes
(i.e., contemporaneous measurement for 15 minutes postcool-
ing). Mobile thermography did not allow for continuous video
images to be obtained, and thus single images from which data
could be extracted were acquired at set time points: baseline, 0
minutes after cold challenge, and 15 minutes after cold challenge.
At the end of the 15 minutes, 1 extra image was obtained for
LSCI and standard thermography, to allow the reperfusion/
rewarming gradient from the last data point to be calculated;
thus, a total of 225 images/scans were obtained for LSCI, 61
for thermography, and 3 for mobile thermography during the
15 minutes of measurement.
Analysis of the images was performed using Moor
Instruments Laser Perfusion Imager software (version 4.0) for
LSCI, and Research IR Max (version 4.2; FLIR) for standard
and mobile thermography. Patients completed the RCS (pos-
sible score range 0–10) at each visit (a measure referred to as
“RCS on the day”), measuring the severity and impact of
their RP for that day (24).
The cold challenge was repeated 1 day later (on day
2), as close as possible to the same time of day in order to
minimize variation due to circadian rhythms (27). The repeti-
tion over 2 consecutive days (i.e., ~24 hours) minimized any
variations within individuals over time (e.g., menstrual cycle
effects) and seasonal variation in weather (28). Five centers
had 1 observer, while 1 center had 2 observers. Each exam-
iner re-examined the same subject on days 1 and 2; for exam-
ple, at the central site, 1 observer imaged 60 patients, twice,
on consecutive days. Figure 3 shows the study design.
A B
C D
Figure 1. A, Photograph of the imaging equipment set up to allow
simultaneous imaging, showing laser speckle contrast imaging (LSCI),
standard thermography, and mobile thermography. B, Baseline image
of the hands obtained with standard thermography, showing distal
dorsal difference (DDD) regions of interest, with fingers being cooler
than dorsum. C, An example of hands imaged by mobile thermogra-
phy at 0 minutes post–cold challenge, with fingers being cooler than
dorsum (scale unavailable for image due to the software used). D, An
example of hands undergoing rewarming (same subject as in B)
imaged by the standard thermal camera at 0 minutes, 7.5 minutes,
and 15 minutes after cooling. Scale on the right refers to the temper-
ature range (20–37°C) shown in B and D.
Figure 2. A, Laser speckle contrast imaging (LSCI) reperfusion
graphs for 8 digits (regions of interest [ROIs] 1–4 and 6–9, as shown
in B) and 2 dorsa (ROIs 5 and 10). Graphs show reperfusion post–cold
challenge (i.e., flux, which was proportional to the product of the aver-
age speed of the blood cells and their concentration, expressed in arbi-
trary perfusion units) versus time. B, Example of a flux image (i.e.,
perfusion map) showing ROIs marked (as described in Figure 1). C,
Photograph of the hands showing the ROIs assessed by LSCI.
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Image analysis for summary measures of response.
Image analysis was carried out locally by an internal, nonblinded
observer at each center. These were the same observers who had
obtained the images. Regions of interest (ROIs) (Figures 1B
and 2B and C) were highlighted in the baseline (pre–cold chal-
lenge) image and in sequential images for 15 minutes postcool-
ing. The distal dorsal difference (DDD) (defined as the
difference in measurements between the dorsum and the finger,
with DDDL, DDDT, and DDDM representing the values based
on LSCI, standard thermography, and mobile thermography,
respectively) (29,30) was calculated for each finger at baseline.
In the sequential images, the ROIs were confined to the 8 distal
phalanges. The area under the curve (AUC) for reperfusion/
rewarming in each finger (with AUCL, AUCT, and AUCM repre-
senting the values based on LSCI, standard thermography, and
mobile thermography, respectively) was calculated manually, not
by automation (Figure 4) (standard thermography), from 61
postchallenge images. In addition, the maximum blood flow
rate/skin temperature after rewarming (MAX; with MAXL,
MAXT, and MAXM representing the values based on LSCI, stan-
dard thermography, and mobile thermography, respectively) and
the gradient of reperfusion/rewarming in the first 2 minutes
post–cold challenge (GRAD; with GRADL, GRADT, and
GRADM representing the values based on LSCI, standard ther-
mography, and mobile thermography, respectively) were deter-
mined. Data were averaged for all fingers, as was done in
previous studies (16). For mobile thermography, the DDD was
obtained from the first of 3 images, and the AUC was approxi-
mated by averaging the data over the latter 2 images. Analysis
took <1 hour per participant, per visit.
Saved images and ROI local analysis data were also ana-
lyzed by the blinded central observer (TLM). Mobile thermogra-
phy image analysis was carried out only at the central site.
Assessment of feasibility. The feasibility of each tech-
nique was assessed at the end of the study based on the individ-
ual opinion of the clinical scientist or technician. Feasibility was
measured as the ease of use and the ease of analysis (score scale
for each 0–10, where 0 = difficult, 10 = easy), and preference of
LSCI over thermography (standard or mobile thermography) for
acquiring and analyzing images.
Measurement of room temperature. A prerequisite of
the cold challenge, and thus a criterion for center participation,
was a temperature-controlled room at each center. All measure-
ments were obtained in a temperature-controlled room (aimed
at a room temperature of 23°C [ 2°C]. Room temperatures
were recorded with data monitors (TinyTag; Gemini Data Log-
gers) to assess the impact of temperature on measurements, with
an interest in examining whether reliability could be improved
by achieving greater temperature control.
Identification of edge effects from LSCI. It became
apparent when the study began that the blood flow appeared to
be lower at the edges of the LSCI images than in the center. This
implied that the distribution of the laser light across the hands
was not equal, with less light incident toward the edges than at
the center of the image. If true, then the consequence of this
would be an artificially lower value for perfusion in the little fin-
gers (edge of image) (Figure 2B) compared to index fingers
(center of image) in the LSCI images. Thus, this was investigated
further, as detailed below.
Statistical analysis. Sample size calculation. Analyses of
the data were performed using R version 3.2.3 (31). Based on
observations in a previous thermography study (16), a sample
size of 180 patients would allow us to estimate the test–retest
reliability to within 0.05. A full discussion of the sample size cal-
culation and other aspects of the statistical analyses (extended
statistical analysis) are available from the corresponding author
upon request.
Determination of test–retest reliability. To determine the
test–retest reliability of each technique, intraclass correlation
coefficients (ICCs) were obtained using linear mixed effects
models. Each summary measure was included as a dependent
variable, with center included as a fixed effect.
Determination of between-observer reliability. The data
over both visits for each patient were averaged, and the resulting
average values were compared between the central observer and
the center-specific observers by calculating the difference (with
95% confidence interval [95% CI]) in the paired mean values
(details available from the corresponding author upon request).
It is not possible to calculate a valid interobserver ICC from
these data, since it would require at least some of the partici-
pants to have traveled to all sites for imaging and a large subset
of images to be analyzed by all observers (32).
Figure 3. Study design. The images obtained were assessed for con-
vergent validity, test–retest reliability, and interobserver differences.
LSCI = laser speckle contrast imaging.
Figure 4. Example of a reperfusion/rewarming area under the curve
(AUC), maximum blood flow rate/skin temperature after rewarming
(MAX), and gradient of reperfusion/rewarming in the first 2 minutes
post–cold challenge (GRAD) for 1 hand, measured with standard
thermography. The data for the index, middle, ring, and little finger
are shown as 4 solid lines, one for each finger (regions of interest
were confined to the 8 distal phalanges, as indicated in Figure 2B).
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Determination of validity of the techniques. Convergent
validity (one aspect of construct validity) was assessed using
bivariate linear mixed models, which included fixed center terms
and separate random patient intercepts for 1) LSCI and stan-
dard thermography, and 2) standard and mobile thermography.
We estimated the latent correlation coefficients (if the tech-
niques measured the same construct, the latent correlation
would be a rho value of 1). For clarity, the statistical analysis pro-
tocol for this joint model is available from the corresponding
author upon request.
A post hoc analysis was conducted in which the responses
to the RCS corresponding to the study day were assessed for cor-
relation with all measurements, using linear mixed models.
Feasibility data. Descriptive statistics were used to sum-
marize the feasibility data.
Mixed effects models accounting for room temperature.
The mean room temperature at each patient visit was added to
the mixed effects models for each summary measure. ICCs were
recalculated, and these values were compared to the previously
calculated estimates.
Analysis of edge effects. Edge effects were investigated in
a post hoc analysis by calculating the trend across fingers for
LSCI measurements, and then comparing these measurements
to those from thermography. Linear mixed models were used to
assess any linear trends in the measurements from the index fin-
ger to the little finger. Fingers were numbered. Finger-level sum-
mary measures of response were then regressed on finger
number for both LSCI and thermography; this linear approxima-
tion was crude, but sufficient. Random intercept and slope terms
were included to account for the fact that there was variation
from patient to patient in these trends, not attributable to the
imaging techniques. Measurements were standardized prior to
analysis, thereby allowing for comparisons to be made between
LSCI and thermography.
RESULTS
Characteristics of the patients. In total, 159
patients were recruited (60 from the central center, 16–20
from each of the other centers). Among the patients, 157
(99%) fulfilled the American College of Rheumatology/
European League Against Rheumatism 2013 classifica-
tion criteria for SSc (33). The median age of the patients
was 63.3 years (interquartile range [IQR] 53.8–69.5 years)
and 123 (77%) had limited cutaneous SSc (34). The med-
ian disease duration since first non-Raynaud’s symptom
was 9.6 years (IQR 4.5–17.4 years). Of the 159 patients
with SSc, 142 (89%) were receiving treatment with
vasodilators (61 with calcium channel blockers, 27 with
angiotensin-converting enzyme inhibitors, 27 with angio-
tensin II receptor antagonist, 22 with phosphodiesterase 5
inhibitor, 4 with endothelin receptor antagonist, and 1
with nitrates), of whom 35 were receiving ≥1 vasodilator.
Moreover, 4 patients (3%) had previously undergone fin-
ger surgical debridements, 5 (3%) had previously had
amputations, and 30 (19%) had experienced ulcers in the
preceding year.
Test–retest reliability of the techniques. There was
at least moderate to substantial reliability in the DDDL,
DDDM, and DDDT, the AUCL, AUCT, and AUCM, and the
MAXL and MAXT. The GRADL and GRADT had fair to
substantial test–retest reliability (Table 1). The strength of
reliability was assessed according to previously defined score
classifications (see ref. 35), as follows: ICC 0.00–0.20 =
slight, ICC 0.21–0.40 = fair, ICC 0.41–0.60 =moderate, ICC
0.61–0.80 = substantial, and ICC 0.81–1.00 = almost perfect.
However, these classifications are, to some extent, arbitrary
and should be treated as a rough guide.
Reliability between observers.When the data from
each visit, observer, and center, and additionally at the
patient level, were analyzed for reliability (see Supple-
mentary Table 2 and Supplementary Figure 1, available
Table 1. Reliability and validity of LSCI and thermography (standard and mobile phone–based) in patients with systemic sclerosis–related
Raynaud’s phenomenon*
Summary measure
Test–retest reliability Difference in
reliability,
Validity
LSCI
(n = 159)
Standard
thermography
(n = 159)
Mobile phone
thermography
(n = 141)†
LSCI versus
standard
thermography
LCSI and
standard
thermography
Standard and
mobile phone
thermography
Distal dorsal difference 0.67 (0.56, 0.77) 0.58 (0.43, 0.71) 0.61 (0.51, 0.73) 0.08 (0.05, 0.25) 0.65 (0.50, 0.79) 0.90 (0.79, 0.97)
Reperfusion/rewarming
AUClog
0.67 (0.54, 0.76) 0.68 (0.58, 0.80) 0.61 (0.51, 0.72)‡ 0.01 (0.17, 0.11) 0.94 (0.87, 1.00) 0.98 (0.94, 1.00)
MAXlog 0.64 (0.52, 0.75) 0.72 (0.64, 0.81) NA 0.09 (0.21, 0.03) 0.87 (0.77, 0.95) NA
Gradient over first 2 minutes 0.46 (0.40, 0.69) 0.56 (0.40, 0.74) NA 0.09 (0.24, 0.18) 0.52 (0.33, 0.70) NA
* Data for the summary measures of distal dorsal difference, reperfusion/rewarming area under the curve (AUClog), maximum blood flow rate/skin
temperature after rewarming (MAXlog), and gradient of reperfusion/rewarming over the first 2 minutes have been averaged over 8 digits. Values
are the intraclass correlation coefficients (ICCs) (with 95% confidence intervals [95% CIs]) for the test–retest reliability of laser speckle contrast
imaging (LSCI), standard thermography, and mobile phone–based thermography, the difference (with 95% CIs) in ICC point estimates between
LSCI and standard thermography, and the estimated validity, expressed as latent correlation coefficients (with 95% CIs), between LSCI and stan-
dard thermography and between standard and mobile phone thermography. NA = not applicable.
† For mobile phone thermography, 141 data sets were available (n = 18 missing due to technical fault at 2 of the centers).
‡ The AUClog for mobile phone thermography was approximated from the mean values of 2 frames, post–cold challenge of the hand.
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on the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.40457/abstract), we con-
sidered that if the measures were perfectly reliable, the
subplot for each center would look like 2 identical ladder
plots (but it is not expected that the plots would be identi-
cal between centers). Our data suggest that there were sys-
tematic differences between the central observer and one
of the centers (center 2, and possibly center 3 [details
available from the corresponding author upon request]) in
extracting data from LSCI images. For thermography,
agreement between the central and local observer was gen-
erally high for all centers, albeit with a large discrepancy in
the data from several patients at one of their visits (results
available from the corresponding author upon request).
Validity of the techniques. The latent correlation
between LSCI and standard thermography (i.e., evidence
that LSCI and standard thermography measure the same
construct, which, in this case, was blood flow returning to
the finger after cold challenge) was as follows: for the
DDD, q = 0.65 (95% CI 0.50, 0.79); for the reperfusion/re-
warming AUC, q = 0.94 (95% CI 0.87, 1.00); and for the
MAX, q = 0.87 (95% CI 0.77, 0.95). In contrast, for the
GRAD, the latent correlation between LSCI and standard
thermography was only 0.52 (95% CI 0.33, 0.70) (Table 1).
High latent correlation is indicative of convergent validity.
Therefore, a value of 0.7 could be considered high, such
that both the MAX and the AUC displayed strong conver-
gent validity.
Correlation between mobile thermography and
standard thermography was also very high. The latent cor-
relation was 0.98 (95% CI 0.94, 1.00) for the AUC, and
0.90 (95% CI 0.79, 0.97) for the DDD (Table 1). Latent
correlation between LSCI and mobile thermography was
0.86 (95% CI 0.74, 0.97) for the AUC, and 0.49 (95% CI
0.29, 0.66) for the DDD.
With the exception of some weak evidence of a
decreasing DDD as measured on thermography with
increasing RCS score (mean  SEM change in the DDDT
of 0.15  0.07 for a 1-point increase in the RCS), we
found no evidence of correlation between the summary
measures and the RCS.
Feasibility. Standard thermography was deemed
to be more feasible than LSCI (see Discussion). The
proportion of raters giving a score of ≥7 for ease of use
was 50% for LSCI, 75% for standard thermography,
and 38% for mobile thermography. Ease of analysis
was rated as ≥7 by 25% of raters for LSCI and by 50%
of raters for standard thermography. One center pre-
ferred LSCI to thermography for acquiring images, and
1 center preferred LSCI to thermography for analyzing
images. Conversely, the number of centers preferring
standard thermography over LSCI was 3 for acquiring
images, and 4 for analyzing images. The remaining cen-
ters showed no preference.
Models including room temperature. When in-
cluded as a covariate, room temperature was not associ-
ated with any of the summary measures, as measured by
either LSCI or thermography. Additionally, the ICCs
were not affected by the inclusion of room temperature in
the analysis. This does not mean that a regulated room
temperature is not important, but that small changes in
temperature are acceptable (see Supplementary Table 3,
available on the Arthritis & Rheumatology web site
at http://onlinelibrary.wiley.com/doi/10.1002/art.40457/
abstract).
Edge effects. When moving from the thumb to the
little finger on imaging, all of the trends in the AUC,
MAX, and GRAD were in the opposite direction
for the 2 modalities, with a decrease in these val-
ues when assessed by LSCI and an increase in these
values when assessed by thermography (see Supplemen-
tary Table 4, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.40457/abstract) Estimates of the DDD were positive
with both techniques, but this was attenuated on images
obtained by LSCI. This is consistent with the notion of an
edge effect artificially producing lower values for the little
fingers when LSCI is used for imaging. The cause of the
edge effect was attributed to the distribution of light over
the imaging area, due to LSCI being used at the upper
limit of the suggested imaging distance in order to fit both
hands into the imaging area. These data indicate that care
must be taken to understand the variations over the field
of view, so that these can be accounted for; decreasing the
field of view would minimize this effect in future studies.
DISCUSSION
To date, LSCI techniques and thermography have
been insufficiently studied as outcome measures in clini-
cal trials. Those studies in which they have been included
show very little consistency in terms of protocol design
(36–38), choice of dynamic challenge, and extracted out-
come measures, making it difficult to compare results
between studies or establish a standard protocol. The
main finding of our study is that the reliability of both
LSCI and thermography (the AUC and MAX) were suffi-
ciently high for use as study outcome measures. The reli-
ability of the MAXT was slightly superior to the MAXL.
Other than this, there were no substantive differences in
reliability between the 2 techniques.
The AUCM and DDDM showed adequate reliabil-
ity for use as outcome measures. Moreover, there was
strong correlation between mobile thermography and
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standard thermography data. The technique of mobile
thermography was added at a late stage in this project
(since it had only just come on the market). Our reason
for including it was primarily for feasibility assessment.
While it is clear that further work is required to validate
mobile thermography, the performance in the present
study is highly encouraging, because, as a low-cost tool, it
could potentially be readily available for widespread use
among rheumatologists.
Although it was not our primary objective, we
examined differences between observers. Systematic differ-
ences between observers at different centers would not be
particularly problematic for a multicenter randomized con-
trolled trial (RCT), provided that the randomization would
be stratified by center. We note that this should be the
default for any multicenter trial, since differences between
centers may otherwise bias the estimated treatment effect.
This is particularly true in small populations, since simple
randomization is less likely to produce balance within cen-
ters. Standardized training would reduce measurement
variation across centers, and centralized extraction and
analysis of LSCI data, conducted in a blinded manner,
might also minimize variation by removing multiobserver
differences in an RCT setting. Given the small sample size
at each center, we are unable to determine whether truly
systematic differences were observed. Ideally, a study to
assess interobserver reliability would involve participants
having images analyzed by all observers.
Convergence between the techniques was shown to
be very high for the AUC and MAX (particularly for the
AUC). This finding provides evidence that the same
underlying construct is being measured when using these
summaries of response. Convergence appeared to be
weaker (although still moderate) for the DDD. Conver-
gence was weakest for the GRAD, which may be a reflec-
tion of the lag between reperfusion and rewarming,
whereby tissue reperfusion (measured using LSCI) is
translated into skin rewarming (measured using thermog-
raphy), during the 2 minutes immediately following cold
challenge.
Since there is no gold standard to which we may
compare either imaging technique, and we are comparing
2 techniques that measure perfusion by very different
methods (skin temperature and a measure of red blood
cell concentration and speed by light), it is possible to
measure convergence between these techniques for valid-
ity (25). It would be unlikely for these 2 techniques to con-
verge if both of them were poor outcome measures, since
they would both have to be deficient in distinct but very
specific ways, so as to bring the erroneous observations
into alignment. Therefore, we can conclude in this in-
stance that their convergence implies validity.
The OMERACT review of 2003 (18) assessed the
validity of several noninvasive techniques as possible
objective outcome measures, but none was deemed ready
for use in clinical trials. These techniques included nail-
fold capillaroscopy, which is a well-established diagnostic
technique now included in the diagnostic criteria to differ-
entiate primary and secondary RP (34). The microscopy
technique allows visualization of cutaneous capillaries at
the nailbed and identification of the structural changes
characteristic of SSc. However, this is not a substitute for
functional measures of flow (although functional flow and
oxygenation have recently been reported). Plethysmogra-
phy allows the change in vascular volume to be measured
(i.e., detection of a pulse) in combination with cold
challenge. The technique can measure full fields in the
same way as LSCI, but remains unvalidated. There was
no relationship between the summary measures and the
RCS on the day of the study visits, for either LSCI or
thermography.
Patient-centered outcome measures are crucial for
evaluating the effectiveness (rather than just the efficacy)
of treatments. However, patient-centered outcomes often
comprise more “noise” compared to more objective mea-
sures of response, and therefore necessitate larger sample
sizes to ensure adequate power in clinical trials. For small
populations, there is therefore a tension between direct
relevance to patients and feasibility of conducting a trial.
One solution may be to power studies on the basis of
objective measures, such as those considered herein, and
to additionally (and consistently) report patient-centered
outcomes to facilitate an eventual meta-analysis. Another
solution might be to seek confirmatory evidence for the
vasodilatory potential of candidate interventions, using
objective measures, before proceeding to larger, phase III
clinical trials.
The relationship between 2 measures is limited by
the reliability of each (39). Although the relative stability of
the RCS between baseline and follow-up has been observed
in clinical trials/studies (38,40), there has been little work
formally assessing its intraindividual reliability.
With regard to feasibility of the techniques, it has
been noted that LSCI is sensitive to movement, vibrations,
and lighting, indicating the importance of environmental
conditions during the imaging. For mobile thermography,
present limitations in feasibility include the battery life
(LSCI is mains operated but standard thermography is
powered by long-life batteries), a fixed focusing distance,
and lack of analysis for video images, as well as mounting
difficulties; however, if the correlation between mobile and
standard thermography can be replicated in future studies,
these limitations may be acceptable in light of the lower
cost and ambulatory (convenient) nature of the technique.
LSCI AND THERMOGRAPHY AS MEASURES OF HAND COLD CHALLENGE RESPONSE 7
When comparing the feasibility of LSCI to the feasibility of
thermography, it should be noted that most centers were
familiar with thermography but not with LSCI, and there-
fore this may have influenced the assessment of feasibility.
One limitation of the study was that we did not
recruit the planned number of participants, due to a sev-
enth center not participating as planned. However, the
study was designed to be robust to under-recruitment.
Although the 95% CIs for our estimates were wider than
they would have been had the target been met, we were
still able to demonstrate sufficient reliability and conver-
gent validity of the AUC and MAX to observe differences
that would indicate that the performance of DDD was
weaker, and to show that the performance of GRAD was
relatively poor.
In conclusion, our design was relatively pragmatic,
with the aim of establishing the performance of the differ-
ent techniques as they would be employed in a multicenter
clinical trial. Our study successfully established a working
group of tertiary care centers for SSc, and together, the
group developed a consensus calibration and cold challenge
protocol. The summary measures of AUC and MAX both
displayed good reliability and strong convergent validity.
There was a possible advantage of thermography in relation
to the reliability of MAX, although this was not definitive.
We found evidence of edge effects when using LSCI,
although our summary measures appeared to be quite
robust to these in relation to reliability, perhaps suggesting
that these effects were fairly consistent (details available
upon request from the corresponding author).
The results of this study also confirm that small
variations in room temperature are acceptable during the
imaging, and that, subject to further validation, mobile
phone cameras may be a suitable, affordable, and highly
portable alternative to more expensive standard imaging
equipment (although mobile phones are battery operated
and with less functionality [at present] than larger thermal
cameras). The mobile phone data obtained in this study
will facilitate the design of future validation studies assess-
ing mobile thermography–derived outcome measures.
Although the design precluded formal assessment of
interobserver reliability, there was a suggestion of system-
atic differences between the central observer and observ-
ers at some of the centers, highlighting the importance of
image analysis training and potentially a role for central-
ized or automated image analysis. For multicenter RCTs,
we would also recommend that, where possible or appro-
priate, randomization be stratified by center to balance
any center-specific effects and prevent bias.
In summary, LSCI and thermography should
now be incorporated as secondary outcome measures
in upcoming treatment efficacy trials. This will allow
an assessment of responsiveness to treatment as well
as longitudinal validity. The present study leads us to
recommend the summary measures of AUC and
MAX, measured using either thermography or LSCI
(but especially using thermography), as suitable out-
come measures for RCTs in patients with SSc-related
RP.
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